NAA15 polyclonal, anti-human, mouse, rat

Background:
NARG1 (NMDA (N-methyl-δ-aspartate) receptor-regulated gene 1), also known as NATH (N-terminal acetyltransferase), TBDN100 (tubedown-1) or Ga19 (gastric cancer antigen Ga19), is a cytoplasmic protein that contains eight TPR repeats. NARG1 is expressed at high levels in dividing tissues such as bone marrow, testis and embryonal brain and it is overexpressed in papillary thyroid carcinomas. NARG1 interacts with ARD1 or ARD2 forming a complex that exhibits N-terminal (α) acetyltransferase activity. The complex interacts with ribosomal subunits functioning in cotranslational acetylation. During apoptosis, both NARG1 and ARD1 are cleaved by caspases which results in decreased acetyltransferase activity. Knockdown of NARG1 in HeLa cells leads to apoptosis, indicating that properly functioning NARG1 is essential for cell viability. In addition, this suggests NARG1 as a potential target in cancer therapy

Alternative Name:
N-alpha-acetyltransferase 15, NatA auxiliary subunit, Gastric cancer antigen Ga19, N-terminal acetyltransferase, NMDA receptor-regulated protein 1, Protein tubedown-1, Tbdn100, NAA15, GA19, NARG1, NATH, TBDN100

Application Dilution:
WB: 1:500~1:1000

Specificity: NARG1 polyclonal antibody detects endogenous levels of NARG1 protein.

Immunogen:
Synthetic peptide, corresponding Human NARG1.

MW: ~ 101 kDa

Swiss-Prot: Q9BXJ9

Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Format:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

For research use only, not for use in diagnostic procedure.